Retatrutide

How it works

Co-activates GLP-1 receptors (appetite suppression, insulin secretion), GIP receptors (GLP-1 synergy, adipose tissue metabolism), and glucagon receptors (hepatic glucose output, thermogenesis and energy expenditure). The tri-agonism creates additive to synergistic weight loss beyond dual or single agonists.

Benefits

• 24%+ body weight loss in Phase 2 trials — highest in class
• Strong appetite suppression via GLP-1 + GIP signaling
• Increased basal metabolic rate via glucagon receptor activation
• Improved insulin sensitivity and glycemic control
• Favorable lipid profile (reduced triglycerides, LDL)
• Potential liver fat reduction (NASH benefit)
• Cardiovascular risk factor reduction

Dosing

2–12 mg · Once weekly

Phase 2 titration: 2mg → 4mg → 8mg → 12mg (escalate every 4 weeks). Max studied: 12mg/week. Tachycardia is more pronounced than with semaglutide.

Ranges reflect commonly cited research protocols, not a prescription. Dose with a licensed provider.

Reconstitution

Research form: lyophilized powder. Reconstitute with BAC water to 2–4mg/mL. Clinical form: pre-filled syringe (not yet commercially available).

Helix’s free reconstitution calculator gives you the exact draw volume → get the app

Common stacks

Reported side effects

• Nausea, vomiting, diarrhea (dose-dependent, improves with titration)
• Constipation
• Fatigue during titration
• Tachycardia (more pronounced than semaglutide)
• Injection site reactions
• Potential muscle loss without resistance training
• Theoretical: pancreatitis, thyroid C-cell tumors (class warning)

Who it’s for

Adults with obesity who haven't achieved adequate results with semaglutide or tirzepatide. Those wanting maximum weight loss effect. Medical supervision strongly recommended.